SNY
Sanofi
SNY has slightly lower modeled downside risk, despite its lower overall score.
UNH
UnitedHealth Group Incorporated
UNH has the edge over SNY overall, supported by stronger modeled upside and stronger valuation.
SNY Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Strong | |
| Healthy |
SNY's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
SNY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $5.73 | -88% |
| Fair | 19x | $10.07 | -79% |
| Expensive | 31x | $16.50 | -66% |
| Current | 89x | $48.46 | — |
Historical ranges are pointers, not guarantees.
SNY's PE is 89x, but its earnings don't support one, so it isn't a reliable read right now.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH has the edge over SNY in the historical PE scenario, which offers more potential upside but is not a forecast.
SNY Forward outlook
There aren't enough analyst estimates for SNY to show an outlook.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
SNY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $0.54 | -87% |
| Q1 2026 | $2.17 | -27% |
| Q4 2025 | $2.27 | -15% |
| Q3 2025 | $4.28 | +112% |
| Q2 2025 | $4.27 | +127% |
| Q1 2025 | $2.99 | +49% |
| Q4 2024 | $2.66 | +11% |
| Q3 2024 | $2.02 | -50% |
SNY has the edge over UNH on earnings, with more consistent year-over-year improvement.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH's earnings per share have fallen from their peak: $17.55 over the past year, against $23.89 in early 2025.
SNY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $13.7B | +15% |
| Q1 2026 | $12.5B | +6% |
| Q4 2025 | $13.6B | +60% |
| Q3 2025 | $14.6B | -7% |
| Q2 2025 | $11.9B | -5.7% |
| Q1 2025 | $11.8B | +9% |
| Q4 2024 | $8.5B | -37% |
| Q3 2024 | $15.7B | +11% |
SNY's revenue has picked up after three years of holding roughly level: $13.7B last quarter, up 15% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 19% | +5.6 points |
| Q1 2026 | 20% | -0.9 points |
| Q4 2025 | -8.5% | -16 points |
| Q3 2025 | 28% | +1.8 points |
| Q2 2025 | 14% | -0.3 points |
| Q1 2025 | 21% | +8.3 points |
| Q4 2024 | 7.5% | +4.7 points |
| Q3 2024 | 26% | +0.4 points |
SNY has the edge over UNH on profitability, with a higher operating margin.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over SNY on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
SNY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $4.3B | +$4.3B |
| Q1 2026 | $1.9B | -20% |
| Q4 2025 | $1.8B | +$1.8B |
| Q3 2025 | $5.1B | +$5.1B |
| Q2 2025 | $0 | +$458.7M |
| Q1 2025 | $2.3B | +$2.3B |
| Q4 2024 | $0 | -100% |
| Q3 2024 | $0 | $0 |
SNY generated $13.1B in free cash flow over the past year, about six times what it generated the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH still generates free cash flow, though less than at its 2022 peak: $22.8B over the past year.
SNY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.6% | -15.2M shares |
| 1 year | -3% | -74.6M shares |
| 3 years | -4.3% | -108M shares |
| 5 years | -4.4% | -111M shares |
| Available history | -4.4% | -111M shares |
SNY has the edge over UNH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $1.3B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $32.2M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
SNY spent $1.3B buying back its own shares over the past year, after none the year before.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has 902M diluted shares, down 0.7% from a year ago, with $5B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
SNY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 1.2x | Healthy |
| Q1 2026 | 1.0x | Healthy |
| Q4 2025 | 0.9x | Very low |
| Q3 2025 | 1.0x | Healthy |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 1.1x | Healthy |
| Q4 2024 | 1.0x | Very low |
| Q2 2024 | 2.1x | Moderate |
SNY has the edge over UNH on leverage, with a lower net debt burden relative to earnings.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
SNY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.1 | Neutral |
| Stochastic | 86.8 | Overbought |
SNY's weekly RSI is 64 (neutral) and its Stochastic is 87 (overbought).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
SNY PE vs Healthcare Sector
| Metric | SNY | Sector median | Relative |
|---|---|---|---|
| PE | 89x | 26x | 244% above |
| PE % | 100 | 29 | 71 pts above |
SNY is trading at 89x earnings, a 244% premium to the Healthcare sector's median of 26x, though its earnings don't support one.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH has the edge over SNY on valuation relative to its sector.
SNY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $42.9 | 13% above |
| 20 week MA | $43.4 | 12% above |
| 50 week MA | $45.1 | 7.5% above |
| 100 week MA | $47.9 | 1.1% above |
| 200 week MA | $49.4 | 1.9% below |
SNY has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 1.9% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 9.3% below its 200-week average.
SNY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $50.9 | $47.5 | -6.7% |
| 2021 | $47.5 | $49.8 | +5% |
| 2022 | $49.8 | $48.5 | -2.6% |
| 2023 | $48.5 | $49.7 | +2.5% |
| 2024 | $49.7 | $48.7 | -2% |
| 2025 | $48.7 | $48.5 | -0.5% |
| 2026 YTD | $48.5 | $48.5 | 0% |
SNY has finished lower in four of the last six years. It's roughly flat so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over SNY on returns for 2026, with the stronger performance.